Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1832768 | 0.85 | L3MBTL1 (0.72) | ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA | |
| SCHEMBL11536910 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL12793245 | 0.84 | POLB (0.88) | ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA | |
| SCHEMBL2744785 | 0.84 | L3MBTL1 (0.70) | ALDH1A1SMN1; SMN2NPC1L3MBTL1MAPK1 | |
| SCHEMBL6201042 | 0.84 | L3MBTL1 (0.70) | ALDH1A1SMN1; SMN2NPC1L3MBTL1MAPK1 | |
| SCHEMBL2981180 | 0.83 | ALDH1A1 (0.97) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL26313603 | 0.83 | ALDH1A1 (0.97) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14696849 | 0.83 | GLA (0.74) | ALDH1A1SMN1; SMN2L3MBTL1MAPK1LMNA | |
| SCHEMBL12793846 | 0.83 | KMT2A (0.72) | ALDH1A1NPC1L3MBTL1MAPK1LMNA | |
| SCHEMBL27654424 | 0.83 | MAPK1 (0.65) | ALDH1A1MAPTSMN1; SMN2L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071976-B2 | Small molecule fatty acid synthase inhibitors | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-09-11 | — | — | US | disclosed |
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170066731-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | Sanford Burnham Prebys Medical Discovery Institute | 2017-03-09 | — | — | US | disclosed |
| US-20170066731-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | Sanford Burnham Prebys Medical Discovery Institute | 2017-03-09 | — | — | US | disclosed |
| US-20170066731-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | Sanford Burnham Prebys Medical Discovery Institute | 2017-03-09 | — | — | US | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
| WO-2015134790-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015134790-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-09-11 | — | — | WO | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| EP-1608375-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | Signal Pharmaceuticals LLC (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-06-03 | — | — | US | disclosed |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-11-27 | — | — | US | disclosed |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-10-30 | — | — | US | disclosed |
| EP-1349841-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1349840-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002046170-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046171-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | MAPK6, MAPKAPK2, DUSP6 | ALDH1A1 2358/4885MAPT 1178/4885SMN1; SMN2 3049/4885 |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | ALDH1A1 1883/4885MAPT 3895/4885SMN1; SMN2 1078/4885 |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | ALDH1A1 3935/4885MAPT 2390/4885SMN1; SMN2 3620/4885 |
| US-10071976-B2 | Small molecule fatty acid synthase inhibitors | FASN, FADS2, FADS1 | ALDH1A1 831/4885MAPT 3810/4885SMN1; SMN2 4681/4885 |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | MAPK6, MAP3K6, MAPK1 | ALDH1A1 2565/4885MAPT 1474/4885SMN1; SMN2 4094/4885 |
| US-20170066731-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | FASN, FADS2, FADS1 | ALDH1A1 831/4885MAPT 3810/4885SMN1; SMN2 4681/4885 |
| US-20100009973-A1 | Integrase Inhibitors 3 | TYMP, IMPDH1, IMPDH2 | ALDH1A1 1001/4885MAPT 3484/4885SMN1; SMN2 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.